Dr Peter Mace and Professor Sally McCormick have each been awarded more than $1M in the latest round of Health Research council funding.
Peter Mace will use his $1,193,468 to investigate regulation of the polycomb-repressive deubiquitinase (PR-DUB) in cancer. Mutations in components of the PR-DUB protein complex frequently give rise to malignant mesothelioma, melanomas, and renal cell carcinoma, and increase susceptibility to asbestos.
Sally McCormick's $1,185,496 will go towards targeting new receptors for lipoprotein(a), a type of cholesterol-containing package found in the blood, which predisposes to heart attacks in high levels. The long term aim is to develop lipoprotein(a)-lowering therapies.
|
| Professor McCormick and Dr Mace outside the Department of Biochemistry building |
